A Trial Exploring the Opportune Administration of Nab-paclitaxel in the First Line Treatment, Camrelizumab Combined With Nab-paclitaxel and Famitinib, of TNBC.
Metastatic or locally advanced, histologically documented TNBC (absence of HER2, ER, and PR expression)
Cancer stage: recurrent or metastatic breast cancer; Local recurrence be confirmed by the researchers could not be radical resection.
Adequate hematologic and end-organ function, laboratory test results.
Measurable disease according to Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1) • Patients had received no previous chemotherapy or targeted therapy for metastatic triple-negative breast cancer
You may not be if
Previous received anti-VEGFR small molecule tyrosine kinase inhibitors (e.g. famitinib, sorafenib, Sunitinib, regorafenib, etc.) for treatment of the patients .
A history of bleeding, any serious bleeding events.
Important blood vessels around tumors has been infringed and high risk of bleeding.
Coagulant function abnormality
artery/venous thromboembolism event
History of autoimmune disease
Positive test for human immunodeficiency virus
Active hepatitis B or hepatitis C
Uncontrolled pleural effusion and ascites • Known central nervous system (CNS) disease.
Long-term unhealing wound or incomplete healing of fracture
urine protein ≥2+ and 24h urine protein quantitative \> 1 g.
Pregnancy or lactation.
Thyroid dysfunction.
Peripheral neuropathy grade ≥2.
People with high blood pressure;
A history of unstable angina;
New diagnosis of angina pectoris.
Myocardial infarction incident ;
Clareo Health | A Trial Exploring the Opportune Administration of Nab-paclitaxel in the First Line Treatment, Camrelizumab Combined With Nab-paclitaxel and Famitinib, of TNBC.
